Using molecular analysis, we found that 13 out of 21 patients (61.90%) in our cohort have CS-A with mutations in ERCC8 (CS-A), 5 patients have CS-B with mutations in ERCC6, and 3 patients with CS lacking mutations in both genes (unpublished data). The gene discussed is ERCC6; the disease is chromosome-type aberration frequency.